C4 Therapeutics Inc (CCCC)

$2.26 -0.03 (-1.31%)
Market Cap 160.48M
Revenue (ttm) 35.58M
Net Income (ttm) -105.32M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -296.01%
Debt to Equity Ratio 0.00
Volume 570,500
Avg Vol 1,393,270
Day's Range N/A - N/A
Shares Out 71.01M
Stochastic %K 43%
Beta 2.94
Analysts Strong Sell
Price Target $12.93

Company Profile

C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins. Its lead product candidate is Cemsidomide, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 clinical trials targeting IKZF1 and IKZF3 for multiple myeloma and non-Hodgkin lymphomas, including peripheral T-cell lymphoma and mantle cell lymphoma. The company is also developing CFT1946, an orally bioavailable BiDAC degrader targeting BR...

Industry: Biotechnology
Sector: Healthcare
Phone: 617 231 0700
Address:
490 Arsenal Way, Suite120, Watertown, United States
LabPsycho
LabPsycho Jul. 24 at 5:47 PM
$CCCC @Bromberger See my post below...I do think something is brewing (good or bad) with slightly favorable odds to the upside in my opinion. IMO, Pros: Lows moving up and stock up 60% in a few weeks. Cons: Seems like very little support on these retraces Ambiguous: Compare movement of TNGX (about same size, shares, cash as $CCCC) starting last April - as I recall it also had some wild swings esp early on as it climbed from ~ 1.28 to now almost $7 in just a couple of months. Good luck.
1 · Reply
Bromberger
Bromberger Jul. 24 at 3:29 PM
$CCCC Volatile as hell, but it’s heading in the right direction.
0 · Reply
LabPsycho
LabPsycho Jul. 24 at 2:43 PM
$CCCC @Andysss The what I would consider inordinate large swings in CCCC price action lately - as a function of its volume, i.e. +/- 7-10% some days on less than average for CCCC [but still CCCC showing above average trading volume vs other similar sized biotechs] IMO suggests a larger move is in the works, slightly favored to the upside rather than downside. Good luck
0 · Reply
Filvul
Filvul Jul. 24 at 1:59 PM
$IOVA $ACRV $AUTL $ATYR $CCCC
0 · Reply
lola269
lola269 Jul. 24 at 1:58 PM
Yayy coordinated short attack and what do we do in instances like these?? We buy like fucking degenerates Lfg!! $IOVA $ACRV $AUTL $ATYR $CCCC
0 · Reply
NapoleonOfFinance
NapoleonOfFinance Jul. 24 at 12:14 PM
$CCCC I will keep adding to this @LabPsycho @mhparvez
1 · Reply
Andysss
Andysss Jul. 24 at 9:37 AM
$CCCC Options flow shows a strong call-side bias with near-zero put/call ratios and subdued IV. Bullish setup, but we need volume to confirm the breakout. 80% institutional ownership setting the stage for significant retail-driven volume surges on technical breakouts.
0 · Reply
LabPsycho
LabPsycho Jul. 23 at 2:30 PM
$CCCC @danimelo is batting 100% on CCCC calls. Great contributions.
0 · Reply
LabPsycho
LabPsycho Jul. 23 at 2:27 PM
$CCCC @Andysss Knows how to time a trade - see below. Impressive indeed.
0 · Reply
VNVRCH
VNVRCH Jul. 23 at 2:25 PM
$CCCC let's see if it breaks 2.45, high ask limit volumes from OB data.
1 · Reply
Latest News on CCCC
C4 Therapeutics: An Entry Point If There's Ever Going To Be One

Jun 16, 2025, 1:50 PM EDT - 5 weeks ago

C4 Therapeutics: An Entry Point If There's Ever Going To Be One

C4 Therapeutics Reports First Quarter 2025 Financial Results and Recent Business Highlights

May 7, 2025, 7:00 AM EDT - 2 months ago

C4 Therapeutics Reports First Quarter 2025 Financial Results and Recent Business Highlights

C4 Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights

Feb 27, 2025, 7:00 AM EST - 5 months ago

C4 Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights

C4 Therapeutics to Participate in Upcoming March Investor Conferences

Feb 24, 2025, 7:00 AM EST - 5 months ago

C4 Therapeutics to Participate in Upcoming March Investor Conferences

C4 Therapeutics Presents Cemsidomide Phase 1 Data at the American Society for Hematology (ASH) Annual Meeting that Demonstrated Potential to Become Best-in-Class IKZF1/3 Degrader

Dec 8, 2024, 12:30 PM EST - 8 months ago

C4 Therapeutics Presents Cemsidomide Phase 1 Data at the American Society for Hematology (ASH) Annual Meeting that Demonstrated Potential to Become Best-in-Class IKZF1/3 Degrader

C4 Therapeutics Appoints Accomplished Oncology Executive Steve Hoerter to Board of Directors

Nov 20, 2024, 7:00 AM EST - 8 months ago

C4 Therapeutics Appoints Accomplished Oncology Executive Steve Hoerter to Board of Directors

C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Oct 28, 2024, 4:01 PM EDT - 9 months ago

C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

C4 Therapeutics Appoints Paige Mahaney, Ph.D., as Chief Scientific Officer and Announces Retirement of Stewart Fisher, Ph.D.

Oct 15, 2024, 4:01 PM EDT - 10 months ago

C4 Therapeutics Appoints Paige Mahaney, Ph.D., as Chief Scientific Officer and Announces Retirement of Stewart Fisher, Ph.D.

C4 Therapeutics Announces Presentations and Participation in 7th Annual Targeted Protein Degradation & Induced Proximity Summit

Oct 9, 2024, 7:00 AM EDT - 10 months ago

C4 Therapeutics Announces Presentations and Participation in 7th Annual Targeted Protein Degradation & Induced Proximity Summit

C4 Therapeutics Presents Monotherapy Data Demonstrating Proof of Mechanism and Early Evidence of Proof of Concept From Ongoing CFT1946 Phase 1 Trial in BRAF V600 Mutant Solid Tumors at the European Society for Medical Oncology (ESMO) Congress 2024

Sep 13, 2024, 10:00 AM EDT - 11 months ago

C4 Therapeutics Presents Monotherapy Data Demonstrating Proof of Mechanism and Early Evidence of Proof of Concept From Ongoing CFT1946 Phase 1 Trial in BRAF V600 Mutant Solid Tumors at the European Society for Medical Oncology (ESMO) Congress 2024

C4 Therapeutics to Present Preliminary CFT1946 Monotherapy Phase 1 Clinical Data at the European Society for Medical Oncology (ESMO) Congress 2024

Sep 8, 2024, 6:05 PM EDT - 11 months ago

C4 Therapeutics to Present Preliminary CFT1946 Monotherapy Phase 1 Clinical Data at the European Society for Medical Oncology (ESMO) Congress 2024

C4 Therapeutics Appoints Veteran Biotechnology Leader Stephen Fawell, Ph.D. to Board of Directors

Sep 3, 2024, 7:00 AM EDT - 11 months ago

C4 Therapeutics Appoints Veteran Biotechnology Leader Stephen Fawell, Ph.D. to Board of Directors

C4 Therapeutics to Participate in Upcoming September Investor Conferences

Aug 29, 2024, 7:00 AM EDT - 11 months ago

C4 Therapeutics to Participate in Upcoming September Investor Conferences

C4 Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights

Aug 1, 2024, 7:00 AM EDT - 1 year ago

C4 Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights

C4 Therapeutics to Present Preliminary Monotherapy Data from the Ongoing Phase 1 Trial of CFT1946 as a Mini Oral Presentation at the ESMO Congress 2024

Jul 16, 2024, 4:01 PM EDT - 1 year ago

C4 Therapeutics to Present Preliminary Monotherapy Data from the Ongoing Phase 1 Trial of CFT1946 as a Mini Oral Presentation at the ESMO Congress 2024

C4 Therapeutics to Participate in the Virtual UBS Targeted Protein Degradation Day

Jul 8, 2024, 7:00 AM EDT - 1 year ago

C4 Therapeutics to Participate in the Virtual UBS Targeted Protein Degradation Day

C4 Therapeutics Appoints Ron Cooper as Chairman of the Board of Directors

Jun 10, 2024, 7:00 AM EDT - 1 year ago

C4 Therapeutics Appoints Ron Cooper as Chairman of the Board of Directors

C4 Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights

May 8, 2024, 7:00 AM EDT - 1 year ago

C4 Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights

C4 Therapeutics to Participate in the Stifel 2024 Targeted Oncology Forum

Apr 9, 2024, 7:00 AM EDT - 1 year ago

C4 Therapeutics to Participate in the Stifel 2024 Targeted Oncology Forum

C4 Therapeutics Presents New Preclinical Data for CFT1946 Highlighting Superior Activity as a Single Agent to Clinically Approved BRAF Inhibitor Standard of Care Combinations at the American Association for Cancer Research Annual Meeting 2024

Apr 8, 2024, 8:00 AM EDT - 1 year ago

C4 Therapeutics Presents New Preclinical Data for CFT1946 Highlighting Superior Activity as a Single Agent to Clinically Approved BRAF Inhibitor Standard of Care Combinations at the American Association for Cancer Research Annual Meeting 2024

C4 Therapeutics to Present New Preclinical Data on Highly Selective Orally Bioavailable BiDAC™ Degraders at the American Association for Cancer Research Annual Meeting 2024

Mar 5, 2024, 4:30 PM EST - 1 year ago

C4 Therapeutics to Present New Preclinical Data on Highly Selective Orally Bioavailable BiDAC™ Degraders at the American Association for Cancer Research Annual Meeting 2024

C4 Therapeutics Announces Strategic Discovery Research Collaboration with Merck KGaA, Darmstadt, Germany, Against Critical Oncogenic Proteins

Mar 4, 2024, 7:00 AM EST - 1 year ago

C4 Therapeutics Announces Strategic Discovery Research Collaboration with Merck KGaA, Darmstadt, Germany, Against Critical Oncogenic Proteins

C4 Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights

Feb 22, 2024, 7:00 AM EST - 1 year ago

C4 Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights

C4 Therapeutics Announces 2024 Priorities and Extended Cash Runway to Advance Portfolio of Targeted Protein Degradation Medicines

Jan 9, 2024, 4:01 PM EST - 1 year ago

C4 Therapeutics Announces 2024 Priorities and Extended Cash Runway to Advance Portfolio of Targeted Protein Degradation Medicines

C4 Therapeutics Announces Closing of $25 Million Equity Investment by Betta Pharmaceuticals

Jan 4, 2024, 4:01 PM EST - 1 year ago

C4 Therapeutics Announces Closing of $25 Million Equity Investment by Betta Pharmaceuticals

C4 Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference

Jan 4, 2024, 7:00 AM EST - 1 year ago

C4 Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference

C4 Therapeutics Announces Positive Data from CFT7455 Phase 1 Trial in Relapsed/Refractory Multiple Myeloma

Dec 12, 2023, 4:01 PM EST - 1 year ago

C4 Therapeutics Announces Positive Data from CFT7455 Phase 1 Trial in Relapsed/Refractory Multiple Myeloma

C4 Therapeutics Announces License and Research Collaboration with Merck to Discover and Develop Degrader-Antibody Conjugates (DACs)

Dec 12, 2023, 7:00 AM EST - 1 year ago

C4 Therapeutics Announces License and Research Collaboration with Merck to Discover and Develop Degrader-Antibody Conjugates (DACs)

C4 Therapeutics to Host Webcast to Present New Dose Escalation Data from CFT7455 Phase 1 Study in Relapsed/Refractory Multiple Myeloma

Nov 28, 2023, 7:00 AM EST - 1 year ago

C4 Therapeutics to Host Webcast to Present New Dose Escalation Data from CFT7455 Phase 1 Study in Relapsed/Refractory Multiple Myeloma

C4 Therapeutics Strengthens Board of Directors with Owen Hughes Appointment

Nov 20, 2023, 7:00 AM EST - 1 year ago

C4 Therapeutics Strengthens Board of Directors with Owen Hughes Appointment

C4 Therapeutics Reports Third Quarter 2023 Financial Results and Recent Business Highlights

Nov 1, 2023, 7:00 AM EDT - 1 year ago

C4 Therapeutics Reports Third Quarter 2023 Financial Results and Recent Business Highlights

C4 Therapeutics Announces Upcoming Data Presentations for CFT8634, an Orally Bioavailable BiDAC™ Degrader in Development for Synovial Sarcoma and SMARCB1-Null Tumors, and CFT7455, an Orally Bioavailable MonoDAC™ Degrader in Development for Multiple Myelom

Oct 11, 2023, 7:00 AM EDT - 1 year ago

C4 Therapeutics Announces Upcoming Data Presentations for CFT8634, an Orally Bioavailable BiDAC™ Degrader in Development for Synovial Sarcoma and SMARCB1-Null Tumors, and CFT7455, an Orally Bioavailable MonoDAC™ Degrader in Development for Multiple Myelom

C4 Therapeutics Announces Chief Financial Officer Succession

Sep 5, 2023, 4:01 PM EDT - 2 years ago

C4 Therapeutics Announces Chief Financial Officer Succession

C4 Therapeutics Reports Second Quarter 2023 Financial Results and Recent Business Highlights

Aug 8, 2023, 7:00 AM EDT - 2 years ago

C4 Therapeutics Reports Second Quarter 2023 Financial Results and Recent Business Highlights

C4 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Jul 15, 2023, 1:58 AM EDT - 2 years ago

C4 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

C4 Therapeutics Announces FDA Clearance of Investigational New Drug Application for CFT8919, an Orally Bioavailable BiDAC™ Degrader Targeting EGFR L858R for Non-Small Cell Lung Cancer

Jul 5, 2023, 7:00 AM EDT - 2 years ago

C4 Therapeutics Announces FDA Clearance of Investigational New Drug Application for CFT8919, an Orally Bioavailable BiDAC™ Degrader Targeting EGFR L858R for Non-Small Cell Lung Cancer

C4 Therapeutics Appoints Leonard Reyno, M.D., as Chief Medical Officer

Jun 20, 2023, 7:00 AM EDT - 2 years ago

C4 Therapeutics Appoints Leonard Reyno, M.D., as Chief Medical Officer

C4 Therapeutics and Betta Pharmaceuticals Announce Exclusive Licensing Agreement for the Development and Commercialization in Greater China of CFT8919, an Orally Bioavailable BiDAC™ Degrader of EGFR L858R for NSCLC

May 30, 2023, 7:00 AM EDT - 2 years ago

C4 Therapeutics and Betta Pharmaceuticals Announce Exclusive Licensing Agreement for the Development and Commercialization in Greater China of CFT8919, an Orally Bioavailable BiDAC™ Degrader of EGFR L858R for NSCLC

C4 Therapeutics Reports First Quarter 2023 Financial Results and Recent Business Highlights

May 4, 2023, 7:00 AM EDT - 2 years ago

C4 Therapeutics Reports First Quarter 2023 Financial Results and Recent Business Highlights

C4 Therapeutics to Participate in the Stifel 2023 Virtual Targeted Oncology Days

Apr 19, 2023, 7:00 AM EDT - 2 years ago

C4 Therapeutics to Participate in the Stifel 2023 Virtual Targeted Oncology Days

C4 Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Business Highlights

Feb 23, 2023, 7:00 AM EST - 2 years ago

C4 Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Business Highlights

C4 Therapeutics to Present at Two Virtual February 2023 Conferences

Feb 8, 2023, 7:00 AM EST - 2 years ago

C4 Therapeutics to Present at Two Virtual February 2023 Conferences

C4 Therapeutics Announces First Patient Dosed in Phase 1/2 Clinical Trial Evaluating CFT1946, an Orally Bioavailable BiDAC™ Degrader, in BRAF V600 Mutant Solid Tumors

Jan 30, 2023, 7:00 AM EST - 2 years ago

C4 Therapeutics Announces First Patient Dosed in Phase 1/2 Clinical Trial Evaluating CFT1946, an Orally Bioavailable BiDAC™ Degrader, in BRAF V600 Mutant Solid Tumors

C4 Therapeutics Announces 2023 Strategic Priorities to Advance Portfolio of Targeted Protein Degradation Medicines

Jan 9, 2023, 7:00 AM EST - 2 years ago

C4 Therapeutics Announces 2023 Strategic Priorities to Advance Portfolio of Targeted Protein Degradation Medicines

C4 Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference

Jan 3, 2023, 7:00 AM EST - 2 years ago

C4 Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference

C4 Therapeutics Reports Third Quarter 2022 Financial Results and Recent Business Highlights

Nov 3, 2022, 7:00 AM EDT - 2 years ago

C4 Therapeutics Reports Third Quarter 2022 Financial Results and Recent Business Highlights

C4 Therapeutics Receives Study May Proceed Letter from U.S. FDA to Initiate Phase 1/2 Clinical Trial of CFT1946, an Orally Bioavailable BiDAC™ Degrader, in BRAF-V600 Mutant Solid Cancers

Sep 29, 2022, 7:00 AM EDT - 3 years ago

C4 Therapeutics Receives Study May Proceed Letter from U.S. FDA to Initiate Phase 1/2 Clinical Trial of CFT1946, an Orally Bioavailable BiDAC™ Degrader, in BRAF-V600 Mutant Solid Cancers

C4 Therapeutics to Present at Bank of America Securities Precision Oncology Conference 2022

Sep 26, 2022, 7:00 AM EDT - 3 years ago

C4 Therapeutics to Present at Bank of America Securities Precision Oncology Conference 2022

C4 Therapeutics Reports Second Quarter 2022 Financial Results and Recent Business Highlights

Aug 4, 2022, 8:00 AM EDT - 3 years ago

C4 Therapeutics Reports Second Quarter 2022 Financial Results and Recent Business Highlights

C4 Therapeutics Appoints Experienced Clinical Development Leaders Laura Bessen, M.D. and Donna Grogan, M.D.

Aug 2, 2022, 8:00 AM EDT - 3 years ago

C4 Therapeutics Appoints Experienced Clinical Development Leaders Laura Bessen, M.D. and Donna Grogan, M.D.

LabPsycho
LabPsycho Jul. 24 at 5:47 PM
$CCCC @Bromberger See my post below...I do think something is brewing (good or bad) with slightly favorable odds to the upside in my opinion. IMO, Pros: Lows moving up and stock up 60% in a few weeks. Cons: Seems like very little support on these retraces Ambiguous: Compare movement of TNGX (about same size, shares, cash as $CCCC) starting last April - as I recall it also had some wild swings esp early on as it climbed from ~ 1.28 to now almost $7 in just a couple of months. Good luck.
1 · Reply
Bromberger
Bromberger Jul. 24 at 3:29 PM
$CCCC Volatile as hell, but it’s heading in the right direction.
0 · Reply
LabPsycho
LabPsycho Jul. 24 at 2:43 PM
$CCCC @Andysss The what I would consider inordinate large swings in CCCC price action lately - as a function of its volume, i.e. +/- 7-10% some days on less than average for CCCC [but still CCCC showing above average trading volume vs other similar sized biotechs] IMO suggests a larger move is in the works, slightly favored to the upside rather than downside. Good luck
0 · Reply
Filvul
Filvul Jul. 24 at 1:59 PM
$IOVA $ACRV $AUTL $ATYR $CCCC
0 · Reply
lola269
lola269 Jul. 24 at 1:58 PM
Yayy coordinated short attack and what do we do in instances like these?? We buy like fucking degenerates Lfg!! $IOVA $ACRV $AUTL $ATYR $CCCC
0 · Reply
NapoleonOfFinance
NapoleonOfFinance Jul. 24 at 12:14 PM
$CCCC I will keep adding to this @LabPsycho @mhparvez
1 · Reply
Andysss
Andysss Jul. 24 at 9:37 AM
$CCCC Options flow shows a strong call-side bias with near-zero put/call ratios and subdued IV. Bullish setup, but we need volume to confirm the breakout. 80% institutional ownership setting the stage for significant retail-driven volume surges on technical breakouts.
0 · Reply
LabPsycho
LabPsycho Jul. 23 at 2:30 PM
$CCCC @danimelo is batting 100% on CCCC calls. Great contributions.
0 · Reply
LabPsycho
LabPsycho Jul. 23 at 2:27 PM
$CCCC @Andysss Knows how to time a trade - see below. Impressive indeed.
0 · Reply
VNVRCH
VNVRCH Jul. 23 at 2:25 PM
$CCCC let's see if it breaks 2.45, high ask limit volumes from OB data.
1 · Reply
hk042
hk042 Jul. 23 at 2:24 PM
$CCCC
0 · Reply
Andysss
Andysss Jul. 23 at 11:55 AM
$CCCC I have decided to average up ahead of $2.42 breakout. WMSR at -100 flags extreme oversold with bullish reversal. Support at $2.00 is holding, with rising inflows and strong institutional backing. Risk/reward justifies early entry before confirmation.
1 · Reply
NapoleonOfFinance
NapoleonOfFinance Jul. 22 at 4:19 PM
$IXHL exploded up 30% since discovered. $CCCC and $DNA also in the uptrend bull campaign. Make money everyone . @mhparvez
0 · Reply
NapoleonOfFinance
NapoleonOfFinance Jul. 22 at 2:17 PM
$CCCC $QBTS seems like profit shorting QBTS will be high @mhparvez @lola269
0 · Reply
LabPsycho
LabPsycho Jul. 22 at 2:12 PM
$CCCC @danimelo You were right the previous time before it ran last Friday.
0 · Reply
jaynes19
jaynes19 Jul. 22 at 2:00 PM
$CCCC got that $2.20 gap filled at least
0 · Reply
Avivo
Avivo Jul. 22 at 1:46 PM
$CCCC dead volume today Im starting to think if we don’t get some good news on this one, we are looking at a dead cat bounce.
0 · Reply
lola269
lola269 Jul. 22 at 1:11 PM
$IOVA they will try to fuck us today They'll probably fail, stay strong mates! $ACRV getting there slowly and sensually $AUTL no move on good news! That's that biotech charm, don't get discouraged, it's heavily controlled , we are getting there. $ATYR last patient, open road till verdict. Got a nice dip too, added $CCCC finding support through a bull run is 10/10 experience, recommend Lfg!
1 · Reply
danimelo
danimelo Jul. 22 at 11:15 AM
$CCCC institutionals are accumulating, don’t sell your shares for pennies
1 · Reply
NapoleonOfFinance
NapoleonOfFinance Jul. 21 at 7:19 PM
$CCCC this type of stocks is like still water surface — once there’s good news all the shareholders will conspire to sell at $10+ thus destroying a lot of bears AND causing tremendous momentum to catch the trend followers too.
0 · Reply
LabPsycho
LabPsycho Jul. 21 at 2:52 PM
$CCCC For entertainment and amusement (mostly my own) purposes only, LabPsycho's Artificial Artificial Intelligence (A.^2 I. has this hitting $2.80 soon.
0 · Reply
NapoleonOfFinance
NapoleonOfFinance Jul. 21 at 2:43 PM
$BULL $CCCC the strategy for these 2 stocks is “keep buying”
0 · Reply